Grace Therapeutics Net Income
| GRCE Stock | 3.48 0.20 5.43% |
As of the 5th of February, Grace Therapeutics retains the market risk adjusted performance of 0.8454, and Risk Adjusted Performance of 0.0623. Grace Therapeutics technical analysis makes it possible for you to employ historical prices and volume momentum with the intention to determine a pattern that calculates the direction of the firm's future prices. Please check out Grace Therapeutics jensen alpha, semi variance, and the relationship between the standard deviation and value at risk to decide if Grace Therapeutics is priced fairly, providing market reflects its last-minute price of 3.48 per share. Given that Grace Therapeutics has jensen alpha of 0.1565, we strongly advise you to confirm Grace Therapeutics's regular market performance to make sure the company can sustain itself at a future point.
Grace Therapeutics Total Revenue |
|
| Last Reported | Projected for Next Year | ||
| Net Loss | -8.6 M | -9 M | |
| Net Loss | -11 M | -11.6 M | |
| Net Loss | (0.71) | (0.75) | |
| Net Income Per E B T | 0.86 | 0.97 |
Grace | Net Income | Build AI portfolio with Grace Stock |
Analyzing Grace Therapeutics's Net Income over time reveals critical patterns in financial health and operational efficiency. This metric helps investors evaluate trends, identify inflection points, and make informed decisions based on historical performance. Understanding how Net Income has evolved provides context for assessing Grace Therapeutics's current valuation and future prospects.
Latest Grace Therapeutics' Net Income Growth Pattern
Below is the plot of the Net Income of Grace Therapeutics over the last few years. Net income is one of the most important fundamental items in finance. It plays a large role in Grace Therapeutics financial statement analysis. It represents the amount of money remaining after all of Grace Therapeutics operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue. It is Grace Therapeutics' Net Loss historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Grace Therapeutics' overall financial position and show how it may be relating to other accounts over time.
| View | Last Reported (9.57 M) | 10 Years Trend |
|
Net Income |
| Timeline |
Grace Net Income Regression Statistics
| Arithmetic Mean | (14,198,995) | |
| Coefficient Of Variation | (83.46) | |
| Mean Deviation | 8,834,827 | |
| Median | (9,819,000) | |
| Standard Deviation | 11,850,714 | |
| Sample Variance | 140.4T | |
| Range | 41.1M | |
| R-Value | (0.31) | |
| Mean Square Error | 135.2T | |
| R-Squared | 0.1 | |
| Significance | 0.22 | |
| Slope | (732,070) | |
| Total Sum of Squares | 2247T |
Grace Net Income History
Other Fundumenentals of Grace Therapeutics
Grace Therapeutics Net Income component correlations
Grace Net Income Driver Correlations
Understanding the fundamental principles of building solid financial models for Grace Therapeutics is extremely important. It helps to project a fair market value of Grace Stock properly, considering its historical fundamentals such as Net Income. Since Grace Therapeutics' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Grace Therapeutics' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Grace Therapeutics' interrelated accounts and indicators.
Click cells to compare fundamentals
Will Pharmaceuticals sector continue expanding? Could Grace diversify its offerings? Factors like these will boost the valuation of Grace Therapeutics. Market participants price Grace higher when confident in its future expansion prospects. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Grace Therapeutics data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Understanding Grace Therapeutics requires distinguishing between market price and book value, where the latter reflects Grace's accounting equity. The concept of intrinsic value - what Grace Therapeutics' is actually worth based on fundamentals - guides informed investors toward better entry and exit points. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Market sentiment, economic cycles, and investor behavior can push Grace Therapeutics' price substantially above or below its fundamental value.
Please note, there is a significant difference between Grace Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Grace Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. In contrast, Grace Therapeutics' trading price reflects the actual exchange value where willing buyers and sellers reach mutual agreement.
Grace Therapeutics 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Grace Therapeutics' stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Grace Therapeutics.
| 11/07/2025 |
| 02/05/2026 |
If you would invest 0.00 in Grace Therapeutics on November 7, 2025 and sell it all today you would earn a total of 0.00 from holding Grace Therapeutics or generate 0.0% return on investment in Grace Therapeutics over 90 days. Grace Therapeutics is related to or competes with Tvardi Therapeutics, Actinium Pharmaceuticals, PDS Biotechnology, CalciMedica Common, Xilio Development, Lantern Pharma, and OnKure Therapeutics. Grace Therapeutics is entity of United States More
Grace Therapeutics Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Grace Therapeutics' stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Grace Therapeutics upside and downside potential and time the market with a certain degree of confidence.
| Downside Deviation | 2.28 | |||
| Information Ratio | 0.0546 | |||
| Maximum Drawdown | 12.43 | |||
| Value At Risk | (2.89) | |||
| Potential Upside | 3.8 |
Grace Therapeutics Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Grace Therapeutics' investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Grace Therapeutics' standard deviation. In reality, there are many statistical measures that can use Grace Therapeutics historical prices to predict the future Grace Therapeutics' volatility.| Risk Adjusted Performance | 0.0623 | |||
| Jensen Alpha | 0.1565 | |||
| Total Risk Alpha | 0.0538 | |||
| Sortino Ratio | 0.0563 | |||
| Treynor Ratio | 0.8354 |
Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Grace Therapeutics' price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Grace Therapeutics February 5, 2026 Technical Indicators
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | 0.0623 | |||
| Market Risk Adjusted Performance | 0.8454 | |||
| Mean Deviation | 1.81 | |||
| Semi Deviation | 2.03 | |||
| Downside Deviation | 2.28 | |||
| Coefficient Of Variation | 1354.7 | |||
| Standard Deviation | 2.35 | |||
| Variance | 5.52 | |||
| Information Ratio | 0.0546 | |||
| Jensen Alpha | 0.1565 | |||
| Total Risk Alpha | 0.0538 | |||
| Sortino Ratio | 0.0563 | |||
| Treynor Ratio | 0.8354 | |||
| Maximum Drawdown | 12.43 | |||
| Value At Risk | (2.89) | |||
| Potential Upside | 3.8 | |||
| Downside Variance | 5.2 | |||
| Semi Variance | 4.13 | |||
| Expected Short fall | (2.17) | |||
| Skewness | 7.0E-4 | |||
| Kurtosis | 0.4947 |
Grace Therapeutics Backtested Returns
Grace Therapeutics appears to be somewhat reliable, given 3 months investment horizon. Grace Therapeutics holds Efficiency (Sharpe) Ratio of 0.12, which attests that the entity had a 0.12 % return per unit of standard deviation over the last 3 months. We have found twenty-eight technical indicators for Grace Therapeutics, which you can use to evaluate the volatility of the firm. Please utilize Grace Therapeutics' market risk adjusted performance of 0.8454, and Risk Adjusted Performance of 0.0623 to validate if our risk estimates are consistent with your expectations. On a scale of 0 to 100, Grace Therapeutics holds a performance score of 9. The company retains a Market Volatility (i.e., Beta) of 0.2, which attests to not very significant fluctuations relative to the market. As returns on the market increase, Grace Therapeutics' returns are expected to increase less than the market. However, during the bear market, the loss of holding Grace Therapeutics is expected to be smaller as well. Please check Grace Therapeutics' sortino ratio, semi variance, and the relationship between the information ratio and value at risk , to make a quick decision on whether Grace Therapeutics' current trending patterns will revert.
Auto-correlation | 0.63 |
Good predictability
Grace Therapeutics has good predictability. Overlapping area represents the amount of predictability between Grace Therapeutics time series from 7th of November 2025 to 22nd of December 2025 and 22nd of December 2025 to 5th of February 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Grace Therapeutics price movement. The serial correlation of 0.63 indicates that roughly 63.0% of current Grace Therapeutics price fluctuation can be explain by its past prices.
| Correlation Coefficient | 0.63 | |
| Spearman Rank Test | 0.47 | |
| Residual Average | 0.0 | |
| Price Variance | 0.02 |
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
| Competition |
Grace Accumulated Other Comprehensive Income
Accumulated Other Comprehensive Income |
|
Based on the recorded statements, Grace Therapeutics reported net income of (9.57 Million). This is 102.8% lower than that of the Pharmaceuticals sector and 113.66% lower than that of the Health Care industry. The net income for all United States stocks is 101.68% higher than that of the company.
Grace Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Grace Therapeutics' direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Grace Therapeutics could also be used in its relative valuation, which is a method of valuing Grace Therapeutics by comparing valuation metrics of similar companies.Grace Therapeutics is currently under evaluation in net income category among its peers.
Grace Therapeutics ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Grace Therapeutics' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Grace Therapeutics' managers, analysts, and investors.Environmental | Governance | Social |
Grace Fundamentals
| Return On Equity | -0.13 | ||||
| Return On Asset | -0.12 | ||||
| Current Valuation | 35.02 M | ||||
| Shares Outstanding | 14.13 M | ||||
| Shares Owned By Insiders | 27.06 % | ||||
| Shares Owned By Institutions | 25.60 % | ||||
| Number Of Shares Shorted | 42.81 K | ||||
| Price To Book | 0.92 X | ||||
| EBITDA | (16.67 M) | ||||
| Net Income | (9.57 M) | ||||
| Total Debt | 5.38 M | ||||
| Book Value Per Share | 4.45 X | ||||
| Cash Flow From Operations | (14.9 M) | ||||
| Short Ratio | 0.39 X | ||||
| Earnings Per Share | (0.52) X | ||||
| Target Price | 12.05 | ||||
| Beta | 0.75 | ||||
| Market Capitalization | 55.84 M | ||||
| Total Asset | 71.99 M | ||||
| Retained Earnings | (220.69 M) | ||||
| Working Capital | 20.78 M | ||||
| Net Asset | 71.99 M |
About Grace Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Grace Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Grace Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Grace Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Grace Therapeutics is a strong investment it is important to analyze Grace Therapeutics' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Grace Therapeutics' future performance. For an informed investment choice regarding Grace Stock, refer to the following important reports:Check out For information on how to trade Grace Stock refer to our How to Trade Grace Stock guide.You can also try the Money Flow Index module to determine momentum by analyzing Money Flow Index and other technical indicators.
Will Pharmaceuticals sector continue expanding? Could Grace diversify its offerings? Factors like these will boost the valuation of Grace Therapeutics. Market participants price Grace higher when confident in its future expansion prospects. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Grace Therapeutics data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Understanding Grace Therapeutics requires distinguishing between market price and book value, where the latter reflects Grace's accounting equity. The concept of intrinsic value - what Grace Therapeutics' is actually worth based on fundamentals - guides informed investors toward better entry and exit points. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Market sentiment, economic cycles, and investor behavior can push Grace Therapeutics' price substantially above or below its fundamental value.
Please note, there is a significant difference between Grace Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Grace Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. In contrast, Grace Therapeutics' trading price reflects the actual exchange value where willing buyers and sellers reach mutual agreement.